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Abstract
Background: Transient receptor potential ankyrin 1 (TRPA1) is a membrane-associated cation channel, widely
expressed in neuronal cells and involved in nociception and neurogenic inflammation. We showed recently that
TRPA1 mediates cartilage degradation and joint pain in the MIA-model of osteoarthritis (OA) suggesting a hitherto
unknown role for TRPA1 in OA. Therefore, we aimed to investigate whether TRPA1 is expressed and functional in
human OA chondrocytes.
Methods: Expression of TRPA1 in primary human OA chondrocytes was assessed by qRT-PCR and Western blot.
The functionality of the TRPA1 channel was assessed by Ca2+-influx measurements. Production of MMP-1, MMP-3,
MMP-13, IL-6, and PGE2 subsequent to TRPA1 activation was measured by immunoassay.
Results: We show here for the first time that TRPA1 is expressed in primary human OA chondrocytes and its
expression is increased following stimulation with inflammatory factors IL-1β, IL-17, LPS, and resistin. Further, the
TRPA1 channel was found to be functional, as stimulation with the TRPA1 agonist AITC caused an increase in Ca2+
influx, which was attenuated by the TRPA1 antagonist HC-030031. Genetic depletion and pharmacological
inhibition of TRPA1 downregulated the production of MMP-1, MMP-3, MMP-13, IL-6, and PGE2 in osteoarthritic
chondrocytes and murine cartilage, respectively.
Conclusions: The TRPA1 cation channel was found to be functionally expressed in primary human OA
chondrocytes, which is an original finding. The presence and inflammatory and catabolic effects of TRPA1 in human
OA chondrocytes propose a highly intriguing role for TRPA1 as a pathogenic factor and drug target in OA.
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Background
Transient receptor potential ankyrin 1 (TRPA1) is a
membrane-associated cation channel which mediates
pain and hyperalgesia [1, 2] and functions as a chemo-
sensor of noxious compounds [3–5]. TRPA1 was first
discovered in 1999 [6] and has since then been found to
be widely expressed in afferent sensory neurons, espe-
cially in Aδ and C fibers of nociceptors [7, 8]. In
addition to pain, TRPA1 also has a role in mediating
neurogenic inflammation [9, 10]. More recently, TRPA1
has been found to be expressed also in some nonneuro-
nal cells such as keratinocytes [11] and synoviocytes [12]
but the functional roles of nonneuronal expression re-
main to be studied.
TRPA1 is activated by numerous exogenous pungent
compounds such as allyl isothiocyanate (AITC) from
mustard oil [5], acrolein from exhaust fumes and to-
bacco smoke [9], and allicin from garlic [3]. Interest-
ingly, TRPA1 is also activated and sensitized by agents
formed endogenously in inflammatory reactions, such as
nitric oxide [13], hydrogen peroxide [14] and nitro-oleic
acid [15]. The activation of TRPA1 causes an influx of
cation ions, particularly Ca2+, into the activated cells
[16] and this elevation of intracellular Ca2+ has been
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shown to trigger an action potential in neuronal cells
[16, 17]. Interestingly, among the many regulatory effects
of the alterations of intracellular Ca2+ concentration, its
increase has also been shown to affect the gene expres-
sion of inflammatory mediators [18–20].
Recent evidence suggests TRPA1 to have a role in in-
flammation through exogenous activation by TRPA1 ag-
onists and also through endogenous mechanisms.
TRPA1 has been shown to mediate carrageenan-induced
inflammatory edema [21], tumor necrosis factor (TNF)-
triggered hyperalgesia [22], airway hyperreactivity and
inflammation [23, 24], and to relate to acute gouty arth-
ritis [25, 26]. Very recently we found that TRPA1 has a
role in mediating acute inflammation, cartilage destruc-
tion, and joint pain in monosodium iodoacetate (MIA)-
induced inflammation and osteoarthritis in the mouse
[27].
Osteoarthritis (OA) is the most common cause of
musculoskeletal disability and pain worldwide and its
prevalence is constantly increasing as the population
ages. OA is a degenerative disease of the joints, which is
characterized by inflammation and hypoxia within the
joint, leading to cartilage degradation, joint deformity,
disability, and pain [28, 29]. OA-related cartilage degrad-
ation is caused by a growing imbalance between the pro-
duction of catabolic, anabolic, and inflammatory
mediators within the joint driven by the increased ex-
pression of matrix-degrading metalloproteinases and
proinflammatory mediators such as interleukin (IL)-6
and prostaglandin E2 (PGE2) [28].
TRPA1 has not previously been investigated in chon-
drocytes. However, factors involved in hypoxia and in-
flammation, such as hydrogen peroxide (H2O2), nitric
oxide (NO), and IL-6 have been shown to upregulate the
expression or activation of TRPA1 in some other cells
[12–14]. Furthermore, the activation of TRPA1 has been
reported to enhance the production of inflammatory fac-
tors [12, 21, 26, 30]. Since there is a hypoxic and inflam-
matory state in OA joints [28, 31], and TRPA1 has been
shown to be involved in the mediation of acute inflam-
mation and cartilage degradation in MIA-induced osteo-
arthritis [27], we hypothesized that TRPA1 is expressed
in the chondrocytes in osteoarthritic joints, where its ac-
tivation could play a vital part in the inflammation and
pathogenesis of OA. In the present study, we tested that
hypothesis by measuring the expression and function of
TRPA1 in primary human OA chondrocytes.
Methods
Cell culture
Primary chondrocyte cultures were carried out as previ-
ously described [32]. Leftover pieces of OA cartilage
from knee joint replacement surgery were used under
full patient consent. The patients in this study fulfilled
the American College of Rheumatology classification cri-
teria for OA [33] and the study was approved by the
Ethics Committee of Tampere University Hospital, Tam-
pere, Finland (reference number R09116), and carried
out in accordance with the Declaration of Helsinki. The
procedures to isolate and culture the primary chondro-
cytes are described in the supplementary data (Add-
itional file 1). During experiments the cells were treated
with IL-1β (R&D Systems Europe Ltd, Abingdon, UK),
IL-17 (R&D Systems Europe Ltd.), lipopolysaccharide
(LPS) (Millipore Sigma, St. Louis, MO, USA), resistin
(BioVision Inc., Milpitas, CA, USA), the TRPA1 antag-
onist HC-030031 (Millipore Sigma) or with combina-
tions of these compounds as indicated.
Immortalized human T/C28a2 chondrocytes [34] were
cultured as described in the supplementary data (Add-
itional file 1). During the experiments T/C28a2 chondro-
cytes were treated with IL-1β (R&D Systems Europe
Ltd), IL-17 (R&D Systems Europe Ltd.), LPS (Millipore
Sigma), HC-030031 (Millipore Sigma) or with combina-
tions of these compounds as indicated.
HEK 293 human embryonic kidney cells (American
Type Culture Collection, Manassas, VA, USA) were cul-
tured as described in the supplementary data (Additional
file 1). The cells were transfected using 0.42 mg/cm2 of
human TRPA1 plasmid DNA (pCMV6-XL4 by Origene,
Rockville, MD, USA) with lipofectamine 2000 (Invitro-
gen, Life Technologies, Carlsbad, CA, USA) according to
the manufacturer’s instructions.
Animals
Wild-type (WT) and TRPA1 knockout (KO) male
B6;129P-Trpa1(tm1Kykw)/J mice (Charles River Labora-
tories, Sulzfeld, Germany) aged 19–22 days were used in
mouse cartilage culture experiments. Mice were housed
under standard conditions (12–12 h light–dark cycle, 22
± 1 °C) with food and water provided ad libitum. Animal
experiments were carried out in accordance with the le-
gislation for the protection of animals used for scientific
purposes (Directive 2010/63/EU) and the experiments
were approved by The National Animal Experiment
Board (reference number UTA 845/712-86). Animals
were sacrificed by carbon monoxide followed by cranial
dislocation.
Mouse cartilage culture
After mice were euthanized, full-thickness articular car-
tilage from femoral heads were removed and cultured as
described in the supplementary data (Additional file 1).
The cartilage pieces were exposed to IL-1β (R&D Sys-
tems Europe Ltd.) or its vehicle for 42 h and thereafter
culture media were collected and matrix metalloprotein-
ase (MMP)-3, IL-6, and PGE2 concentrations were mea-
sured by immunoassay.
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Western blot measurements
After the cell culture experiments, total protein was ex-
tracted, and TRPA1 was immunoprecipitated and ana-
lyzed with Western blot as described in the
supplementary data (Additional file 1). TRPA1 antibody
NB110-40763 (Novus Biologicals, LCC, Littleton, CO,
USA) was used as the primary antibody and goat anti-
rabbit HRP-conjugate (sc-2004, Santa Cruz Biotechnol-
ogy, Inc., Dallas, TX, USA) as the secondary antibody in
the Western blot analysis.
Immunoassay
Concentrations of IL-6, MMP-1, MMP-3, MMP-13 and
PGE2 in medium samples were determined by enzyme-
linked immunosorbent assay (ELISA) with commercial
reagents (PGE2: Cayman Chemical Co., Ann Arbor, MI,
USA; human IL-6: eBioscience Inc. San Diego, CA, USA;
MMP-1, MMP-3, MMP-13 and mouse IL-6: R&D Sys-
tems Europe Ltd).
RNA extraction and quantitative RT-PCR
At the indicated time points, total RNA was extracted
and analyzed by quantitative reverse transcription poly-
merase chain reaction (qRT-PCR) for the expression of
TRPA1 mRNA as described in the supplementary data
(Additional file 1).
Ca2+-influx measurements
TRPA1-mediated Ca2+ influx was measured in HEK293
cells [35] transfected with human TRPA1 plasmid, in
human T/C28a2 chondrocytes, and in primary human
OA chondrocytes as described previously [36]. Briefly,
the cells were loaded with 4 μM fluo-3-acetoxymethyl
ester (Fluo-3-AM, Millipore Sigma) and 0.08 % Pluronic
F-127® (Millipore Sigma in Hanks’ balanced salt solution
(HBSS, Lonza, Verviers, Belgium) containing 1 mg/ml of
bovine serum albumin, 2.5 mM probenecid and 25 mM
HEPES pH 7.2 (all from Millipore Sigma) for 30 min at
room temperature. The intracellular-free Ca2+ levels
were assessed by Victor3 1420 multilabel counter (Per-
kin Elmer, Waltham, MA, USA) at excitation/emission
wavelengths of 485/535 nm. In the experiments, the cells
were first preincubated with the TRPA1 antagonist HC-
030031 (100 μM, Millipore Sigma) or the vehicle for
30 min at +37 °C. Thereafter, the TRPA1 agonist allyl
isothiocyanate (AITC, 50 μM, Millipore Sigma) was
added and the measurements were continued for 30 s
after which a robust Ca2+ influx was induced by applica-
tion of the control ionophore compound ionomycin
(1 μM, Millipore Sigma).
Statistical analysis
Data were analyzed using Graph-Pad InStat version 3.00
software (GraphPad Software, San Diego, CA, USA).
The results are presented as mean + standard error of
the mean (SEM) unless otherwise indicated. Unpaired t
test, paired t test, one-way analysis of variance (ANOVA)
or repeated-measures ANOVA, followed by Dunnett’s
test were used in the statistical analysis. Differences were
considered significant at p < 0.05, p < 0.01, and p < 0.001.
Results
TRPA1 is expressed in primary human OA chondrocytes
and in immortalized human T/C28a2 chondrocyte cell line
Primary human OA chondrocytes and immortalized hu-
man T/C28a2 chondrocyte cell line expressed TRPA1.
The expression was measured by quantitative RT-PCR
on isolated total mRNA using a specific TaqMan assay.
The proinflammatory cytokine IL-1β was found to in-
crease TRPA1 expression in a time-dependent manner:
in primary chondrocytes the expression of TRPA1 in-
creased up to 48 hours and declined thereafter (Fig. 1a),
whereas in the human T/C28a2 chondrocytes the ex-
pression maximum was at 6 hours (Fig. 1b). In addition,
TRPA1 expression was also enhanced by inflammatory
factors IL-17, LPS, and resistin (Fig. 2).
To verify the translation of TRPA1 mRNA into pro-
tein, we extracted total protein from primary human OA
chondrocytes and human T/C28a2 chondrocytes and
performed Western blot analysis. HEK293 cells transi-
ently transfected with TRPA1 plasmid were used as posi-
tive control and the protein was detected with a specific
human TRPA1 antibody. Remarkably, both cell types
were found to express TRPA1 protein as seen in Fig. 3.
Human chondrocytes express a functional TRPA1 channel
To confirm that TRPA1 mRNA and the subsequent pro-
tein expressed by human chondrocytes produces a func-
tional channel, Ca2+-influx measurements were carried
out. Primary human chondrocytes and T/C28a2 chon-
drocytes were cultured with IL-1β, which was found to
stimulate TRPA1 expression, or with its vehicle for 24 h,
and thereafter TRPA1 was activated with the TRPA1
agonist AITC. IL-1β stimulation resulted in an increased
responsiveness to AITC as seen as an enhanced Ca2+ in-
flux, and the selective TRPA1 antagonist HC-030031
was shown to prevent this effect (Fig. 4).
MMP, IL-6 and PGE2 production is downregulated by gen-
etic depletion and pharmacological inhibition of TRPA1
After finding that functional TRPA1 was indeed
expressed in chondrocytes, we aimed to further examine
the possible arthritogenic role of the TRPA1 channel.
We investigated the effect of genetic depletion of TRPA1
on the production of OA-related factors MMP-3, IL-6,
and PGE2 by using articular cartilage samples from
TRPA1-deficient (knockout, KO) and corresponding
wild-type (WT) mice. IL-1β treatment increased MMP-
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3, IL-6, and PGE2 production in cartilage as expected.
Remarkably, this response was significantly attenuated in
the cartilage from the TRPA1 KO mice as compared to
the corresponding WT mice (Fig. 5). Further, we treated
primary human chondrocytes with IL-1β alone and to-
gether with the selective TRPA1 antagonist HC-030031
for 24 h. Interestingly, the selective TRPA1 antagonist
HC-030031 downregulated IL-1β-enhanced MMP-1,
MMP-3, MMP-13, IL-6, and PGE2 production by 25–
45 % (Fig. 6), suggesting that TRPA1 plays a role in the
upregulation of these catabolic and inflammatory factors
in OA cartilage.
Discussion
The findings of the present study suggest a hitherto un-
known role for TRPA1 in the pathogenesis of OA. We
have shown for the first time the expression of the
TRPA1 channel in primary human OA chondrocytes
and in the human T/C28a2 chondrocyte cell line. We
showed the expression of TRPA1 mRNA and protein by
Fig. 1 Primary human OA chondrocytes (a) and human T/C28a2 chondrocyte cell line (b) express TRPA1 mRNA and its expression is enhanced by IL-1 in
a time-dependent manner. Cultures of primary human OA chondrocytes (a) and human T/C28a2 chondrocytes (b) were stimulated with IL-1β (100 pg/ml)
for 0–96 h and 0–24 h, respectively, and thereafter total RNA was extracted. TRPA1 mRNA levels were measured by qRT-PCR, and the results were
normalized against GAPDH mRNA. The mRNA levels are expressed as arbitrary units with the levels measured at 24 h (a; primary OA chondrocytes) or 6 h
(b; T/C28a2 chondrocytes) set as 100 %; and the values at the other time points are related to those values. Primary chondrocyte samples were obtained
from three to five different donors and the experiments were carried out in duplicate. Human T/C28a2 chondrocyte experiments were carried out in
quadruplicate. Results are expressed as mean + SEM. One-way ANOVA followed by Dunnett’s post-test was used in the statistical analysis; **indicates
p< 0.01 compared to the control (0 h) sample. OA osteoarthritis, TRPA1 transient receptor potential ankyrin 1
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qRT-PCR and Western blot, respectively. We were also
able to show that the expressed TRPA1 was functional,
as evidenced by Ca2+-influx measurements. Further, we
found TRPA1 to have a role in mediating the production
of OA-related factors MMP-1, MMP-3, MMP-13, IL-6,
and PGE2 as evidenced by pharmacological inhibition
and genetic depletion of TRPA1.
TRPA1 was first discovered in 1999 in fetal lung fibro-
blasts [6]. Since then it has been mainly studied in differ-
ent afferent sensory neurons such as Aδ and C fibers of
- - -
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-
-
-
-
-
-
-
-
-
- -
-
Fig. 2 TRPA1 mRNA expression is increased following stimulation with inflammatory factors IL-1β, IL-17, LPS, and resistin in primary human OA
chondrocytes (a-d) and in human T/C28a2 chondrocyte cell line (e). Isolated primary human OA chondrocytes were stimulated with IL-1β (1–100 pg/
ml) (a), IL-17 (10–100 ng/ml) (b), LPS (10 ng/ml) (c). and resistin (0.3–3 μg/ml) (d); and human T/C28a2 chondrocytes with IL-1β (1–100 pg/ml), IL-17
(100 ng/ml) and LPS (10 ng/ml) (e) for 24 h; and thereafter total RNA was extracted. TRPA1 mRNA levels were measured by qRT-PCR, and the results
were normalized against GAPDH mRNA levels. The results are expressed as a percentage in comparison to untreated control samples, which was set
as 100 %. Primary chondrocyte samples were obtained from four different donors and the experiments were performed in duplicate. Human T/C28a2
chondrocyte experiments were carried out in quadruplicate. Results are expressed as mean + SEM. Repeated measures ANOVA (a, b, d) and one-way
ANOVA (e) followed by Dunnett’s post-test or paired t test (c) was used in the statistical analysis; *p < 0.05 and **p < 0.01, compared to the untreated
control samples. IL interleukin, LPS lipopolysaccharide, OA osteoarthritis, TRPA1 transient receptor potential ankyrin 1
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nociceptors [7, 8]. More recently, however, TRPA1 has
also been found to be expressed in some nonneuronal
cells such as keratinocytes [11, 37, 38], synoviocytes [12,
39] and airway epithelial and smooth muscle cells [30].
It is noteworthy, that not all of these studies have shown
functionality of the TRPA1 ion channel and some have
only reported the expression of TRPA1 at the mRNA
level. In the present study, we have comprehensively
shown the expression and activation of TRPA1 in hu-
man chondrocytes, to support the criteria set by Fer-
nandes et al. [40]. We were able to show for the first
time the expression of both TRPA1 mRNA and protein
and the functionality of the TRPA1 channel in primary
human OA chondrocytes and in human T/C28a2 chon-
drocyte cell line. This finding is particularly interesting
as in OA joints there is a hypoxic [31] and inflammatory
[28, 41] state and related factors, H2O2, NO, and IL-6,
have previously been shown to upregulate the expression
and activation of TRPA1 [12–14]. According to Hatano
et al. [12] the human TRPA1 promoter has at least six
putative nuclear factor kappa B (NF-kB) binding sites
and ten core hypoxia response elements (HREs), which
are binding sites for hypoxia-inducible factor (HIF) tran-
scription factors. HIFs are known to mediate adaptive
responses to hypoxia as well as to be activated by in-
flammation [42, 43] and the binding of HIFs to consen-
sus HREs on their target genes regulates gene
transcription.
After discovering TRPA1 expression in chondrocytes,
we aimed to investigate whether inflammatory factors/
mechanisms related to the pathogenesis of OA [28, 29]
regulate expression of TRPA1, which would indicate a
role for TRPA1 as a mediator in OA. IL-1β is considered
as a major player in OA associated with cartilage de-
struction. IL-1β is elevated in OA joints and it sup-
presses type II collagen and aggrecan expression,
stimulates the release of MMP-1, MMP-3, and MMP-13,
and induces the production of IL-6 and some other cy-
tokines as well as PGE2 [28]. In part IL-17 feeds forward
these mechanisms as it further induces IL-1β, TNF, and
IL-6 production, upregulates NO and MMPs and down-
regulates proteoglycan levels related to the pathogenesis
of OA [28]. Based on our results, IL-1β and IL-17 both
also induce TPRA1 expression and intriguingly, some of
the IL-1β-induced inflammatory and catabolic effects are
partly mediated by TRPA1. In OA the innate immune
system and in particular toll-like receptors (TLRs) acti-
vated by cartilage matrix degradation products, also play
a significant part in disease progression. Chondrocytes
express TLRs, which trigger major inflammatory path-
ways and are activated by bacterial lipopolysaccharide
(LPS) and damage-associated molecular patterns [29],
and also the adipocytokine resistin known to be
expressed in OA joints [44] has been shown to trans-
duce its effects through toll-like receptor 4 [45]. In the
present study, we found that both LPS and resistin in-
creased expression of TRPA1 in human chondrocytes,
suggesting a TLR-mediated mechanism to enhance
TRPA1 expression in OA cartilage. In support of the
present results, Hatano et al. showed that TRPA1 gene
expression was enhanced in synoviocytes by inflamma-
tory factors TNF-α and IL-1 [12], and the present study
together with that of Hatano et al. [12] suggests a previ-
ously unrecognized mechanism that links TRPA1 as an
inducible factor to joint inflammation.
Activation of TRPA1 results in a substantial influx of
Ca2+ into the stimulated cells [46]. Here we verified the
functionality and activation of the TRPA1 channel in hu-
man chondrocytes by measuring Ca2+ influx using the
TRPA1 agonist AITC as well as the TRPA1 antagonist
HC-030031. As shown previously, elevated intracellular
Ca2+ concentration may affect the expression of inflam-
matory genes both in a direct or indirect manner [20].
In the present study, we found that TRPA1 regulated the
production of inflammatory and catabolic factors,
namely MMP enzymes, IL-6, and PGE2 in chondrocytes.
IL-1-induced MMP-3, IL-6, and PGE2 production in the
cartilage from TRPA1-deficient mice was less than half
β β
Fig. 3 TRPA1 protein is expressed in primary human OA chondrocytes and human T/C28a2 chondrocyte cell line. Chondrocyte cultures were
stimulated with IL-1β (100 pg/ml) for 24 h. Extracted proteins were immunoprecipitated and TRPA1 was detected with Western blot analysis. HEK293
cells transiently transfected with human TRPA1 plasmid were used as a positive control. Representative blot of three independent experiments with
similar results. IL interleukin, TRPA1 transient receptor potential ankyrin 1
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of that found in the cartilage from wild-type mice. Ac-
cordingly, the selective TRPA1 antagonist HC-030031
reduced IL-1-induced MMP-1, MMP-3, MMP-13, IL-6,
and PGE2 production by 25–45 % in primary human
OA chondrocytes. In the latter experiment, the cells
were incubated in the presence of IL-1 and HC-030031
for 24 h; therefore the result may be an underestimate of
the effect of total inhibition of TRPA1 in OA chondro-
cytes because HC-030031 is a reversible TRPA1 antag-
onist with a relatively short half-life [47]. These findings
Fig. 4 The TRPA1 ion channel is functional in primary human OA chondrocytes (a, b) and human T/C28a2 chondrocyte cell line (c) as shown by
TRPA1-mediated Ca2+ influx. Primary human chondrocytes (a, b) and human T/C28a2 chondrocytes (c) were cultured with or without (control)
IL-1β (100 pg/ml) for 24 h. HEK293 cells transfected with plasmids encoding human TRPA1 were used as positive control cells (d). The cells were
loaded with Fluo-3-AM and the TRPA1-mediated Ca2+ influx was measured by Victor3 multilabel counter at excitation/emission wavelengths of
485/535 nm at 1/s frequency. The cells were first preincubated with the TRPA1 antagonist HC-030031 (100 μM) or the vehicle for 30 min at +37 °
C. In the measurements, basal fluorescence was first recorded for 15 s and thereafter the selective TRPA1 agonist allyl isothiocyanate (AITC;
50 μM) was added and the measurement was continued for 30 s after which the control ionophore compound ionomycin (1 μM) was introduced
to the cells. IL-1β stimulation resulted in an elevation in AITC-induced Ca2+ influx compared to unstimulated control cells, and it was attenuated
by the selective TRPA1 antagonist HC-030031. The results were normalized against the background and expressed as mean of eight simultaneous
measurements. Curves in A, C and D express results from one representative experiment. In (b) area under the curve (AUC) from 15 to 45 s was
calculated from measurements of primary chondrocyte from four donors (each with eight repeats). Results are expressed as mean + SEM.
Repeated measures ANOVA followed by Dunnett’s post-test was used in the statistical analysis; **p < 0.01 compared to the IL-1β-treated samples.
IL interleukin, OA osteoarthritis, TRPA1 transient receptor potential ankyrin 1
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are supported by previous studies indicating that TRPA1
activation regulates the production of IL-1 in keratinocytes
[38], IL-6 and IL-8 in synoviocytes [12], and PGE2 along
with leukotriene B4 in fibroblasts and keratinocytes [48].
We have recently found that TRPA1 also regulates the ex-
pression of cyclooxygenase-2 (COX-2) [21, 27] and the pro-
duction of monocyte chemotactic protein-1 (MCP-1), IL-6,
IL-1β, myeloperoxidase (MPO), MIP-1α and MIP-2 in in-
flammatory conditions [26]. The detailed molecular mecha-
nisms of this regulation remain, however, to be studied.
TRPA1 is shown to be involved in pain, hyperalgesia, and
neurogenic inflammation [10, 16, 49, 50]. In OA-related
pain, the role of TRPA1 has been investigated in studies by
Moilanen et al. [27] McGaraughty et al. [51] and Okun et
al. [52] using the MIA-model of OA. The two first-
mentioned studies [27, 51] concluded TRPA1 to contribute
to joint pain in experimental OA. In addition, Moilanen et
al. [27] reported that TRPA1-deficient mice developed less
severe cartilage changes following MIA injections. Accord-
ingly, we showed here that TRPA1 is functionally expressed
in chondrocytes. We also examined the possible functions
of the channel by treating primary chondrocyte cultures
with IL-1β and the selective antagonist HC-030031 [2, 53,
54]. Our results suggest an inflammatory and catabolic role
for TRPA1 in human chondrocytes, as we found inhibition
of TRPA1 to suppress the production of OA-related factors
MMP-1, MMP-3, MMP-13, IL-6, and PGE2. These results
were supported by experiments with cartilage from WT
and TRPA1-deficient mice: following stimulation with IL-
1β MMP-3, IL-6, and PGE2 production was lower in the
cartilage from TRPA1-deficient mice than from WT ani-
mals. These results together suggest that TRPA1-activating
Fig. 5 IL-1β-induced production of MMP-3 (a), IL-6 (b), and PGE2 (c) in the cartilage is attenuated by genetic depletion of TRPA1. Cartilage samples
were obtained from TRPA1-deficient (knockout, KO) and corresponding wild-type (WT) mice. The samples were cultured with and without IL-1β
(100 pg/ml) for 42 h and thereafter the culture medium was collected and analyzed for concentrations of MMP-3, IL-6, and PGE2 by immunoassay. The
results are expressed as mean + SEM, n = 6–9. Unpaired t test was used in the statistical analysis; *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the
WT mice. IL interleukin, MMP matrix metalloproteinase, PGE2 prostaglandin E2, TRPA1 transient receptor potential ankyrin 1
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factors are present in OA joints, and that TRPA1 mediates,
at least partly, OA-related pain, inflammation, and cartilage
destruction in neuronal and nonneuronal cells in the joint.
Conclusions
In conclusion, we found the TRPA1 cation channel to be
functionally expressed in primary human OA chondrocytes
and in part to mediate inflammatory and catabolic effects,
which are both original findings. The inflammatory and hyp-
oxic environment in the OA joint is conducive to enhance
the expression and activation of TRPA1. The presence and
effects of TRPA1 in human OA cartilage as found in the
present study, together with the previous findings on TRPA1
in experimentally induced OA [27, 51] propose an intriguing
role for TRPA1 as a mediator and drug target in OA.
Additional file
Additional file 1: Supplementary data. Supplementary information to
the “Methods”. (DOCX 23 kb)
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by pharmacological inhibition of TRPA1. Primary human OA chondrocytes were stimulated with IL-1β (100 pg/ml) in the presence and absence
of the selective TRPA1 antagonist HC-030031 (100 μM) for 24 h. MMP-1, MMP-3, MMP-13, IL-6, and PGE2 concentrations in the culture media were
measured by immunoassay and the results are expressed as mean + SEM. Samples were obtained from eight patients and the experiments were
carried out in duplicate. Paired t test was used in the statistical analysis; *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the IL-1β-treated
samples. IL interleukin, MMP matrix metalloproteinase, OA osteoarthritis, PGE2 prostaglandin E2, TRPA1 transient receptor potential ankyrin 1
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